Erythrocytes as Carriers of Indinavir: Preparation, Characterization, In vitro and In vivo Pharmacokinetic Evaluation in Rats

DOI:

https://doi.org/10.37285/ijpsn.2017.10.1.2

Authors

  • Bhikshapathi D. V. R. N.
  • Shiva Krishna A
  • Ramesh M
  • Suresh G
  • Jyothi Sri S

Abstract

Indinavir is a protease inhibitor of the human immuno-deficiency virus. Indinavir is commercially available as capsule of 200 mg and 400 mg. Adult dose is 800 mg every 8 h. i.e., 2400 mg per day is equivalent to 6 capsules per day. No other dosage form is available in the market. Sustained release dosage form of indinavir can produce maximum therapeutic effect with minimum side effects and achieve better patient compliance. Various carriers have  been used for the drug targeting among which cellular carriers such as erythrocytes offer greater potential advantages than other system.  The drug is never free in circulation thus reducing toxicity and the drug half-life in circulation increases thus kinetic patterns. Antiretroviral-loaded erythrocytes offer a promising therapy against HIV owing to their potential to deliver this kind of drugs to macrophages and reticulo-endothelial (RES) tissues. The aim of the present investigation was to develop and optimize antiretroviral indinavir encapsulated in rat erythrocytes. In this study, the encapsulation of indinavir by rat erythrocytes prepared and compared with indinavir dissolved in normal saline. The prepared formulations were administered to rats by intravenous route and plasma samples was analysed by LC-MS/MS technique. The pharmacokinetic parameters were calculated using Win-nonlin software. The prepared indinavir loaded erythrocytes showed enhanced bioavailability in equal dose due to higher extent of absorption owing to its retention in erythrocytes and releasing the drug slowly. Indinavir demonstrated a sustained release from loaded erythrocytes over a period of 36 h, which suggests a potential use of the erythrocyte as a slow systemic release system for antiretroviral drugs.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Indinavir, erythrocytes, LC-MS/MS, Reticulo-endothelium system, HIV

Downloads

Published

2017-01-31

How to Cite

1.
D. V. R. N. B, A SK, M R, G S, S JS. Erythrocytes as Carriers of Indinavir: Preparation, Characterization, In vitro and In vivo Pharmacokinetic Evaluation in Rats . Scopus Indexed [Internet]. 2017 Jan. 31 [cited 2024 Dec. 10];10(1):3573-81. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/824

Issue

Section

Research Articles

References

Alpar HO, Salt E, Jolly A, Belaid KA, Irwin WJ (1986). Erythrocytes as a slow release carrier system for propranolol and its prodrugs. J Pharmacy and Pharmacol 38: 117-126.
Field WN (1989). A comparison of the treatment of thyroidectomized rats with free thyroxine and thyroxine encapsulated in erythrocytes. Int J Pharm 51: 175-178.
Green R, Widder KJ (1987). Methods in Enzymology. Academic Press; San Diego. 149.
Guyton AC and Hall JE (1996). Red Blood Cells, Anemia and Polycytemia.Textbook of Medical Physiology. 425-433.
Jain S and Jain NK (1997). Engineered erythrocytes as a drug delivery system. Indian J Pharm Sci 59: 275–281.
Lewis DA and Alpar HO (1984). Therapeutic possibilities of drugs encapsulated in erythrocytes. Int J Pharm. 22: 137-146.
Ropars C, Chassaigne M, Nicolau C (1987). Resealed Erythrocytes as Carriers and Bioreactors. Advances in the biosciences. 67.
Telen MJ and Lee R (1993). The mature erythrocytes. Winthrob’s Clinical Hematology. 101-133.
Torotra GJ and Grabowski SR (1993). The cardiovascular system. The Blood, in Principles of Anatomy and Physiology, Harper Collins College Publishers 566-590.
Zimmermann U (1983). Cellular drug-carrier systems and their possible targeting in targeted drugs. John Wiley & Sons 153-200.

Most read articles by the same author(s)

1 2 > >>